Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3476
Microvision
MVIS
$89.7M
| $169K | ﹤0.01% |
+4,797
| New | +$223K |
|
|
GLDG
3477
GoldMining Inc
GLDG
$226M
| $168K | ﹤0.01% |
148,500
+20,800
| +16% | +$21.8K |
|
3478
Gray Media Inc
GTN.A
$612M
| $168K | ﹤0.01% |
15,400
-1,600
| -9% | -$18.3K |
|
3479
United States Antimony
UAMY
$799M
| $168K | ﹤0.01% |
344,469
+15,370
| +5% | +$5.95K |
|
3480
BlackSky Technology
BKSY
$1.27B
| $167K | ﹤0.01% |
13,563
+5,763
| +74% | +$76.7K |
|
|
PPTA
3481
Perpetua Resources
PPTA
$3.1B
| $167K | ﹤0.01% |
57,214
+38,414
| +204% | +$83.4K |
|
|
SSY
3482
DELISTED
SunLink Health Systems
SSY
| $167K | ﹤0.01% |
274,478
-10,900
| -4% | -$9.03K |
|
|
ICVX
3483
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $167K | ﹤0.01% |
21,000
+5,900
| +39% | +$25.3K |
|
|
EMX
3484
DELISTED
EMX Royalty
EMX
| $166K | ﹤0.01% |
+87,719
| New | +$161K |
|
3485
2x Long VIX Futures ETF
UVIX
$204M
| $166K | ﹤0.01% |
+3
| New | +$274K |
|
3486
Quantum Corp
QMCO
$973M
| $165K | ﹤0.01% |
7,591
+2,388
| +46% | +$58.7K |
|
3487
TRX Gold Corp
TRX
$341M
| $164K | ﹤0.01% |
485,947
+196,054
| +68% | +$71.6K |
|
|
ITRG
3488
Integra Resources
ITRG
$550M
| $163K | ﹤0.01% |
103,240
-23,920
| -19% | -$37.1K |
|
|
SUNL
3489
DELISTED
Sunlight Financial Holdings, Inc.
SUNL
| $161K | ﹤0.01% |
6,255
-520
| -8% | -$14.4K |
|
3490
Werewolf Therapeutics
HOWL
$18.8M
| $160K | ﹤0.01% |
78,223
+59,923
| +327% | +$157K |
|
3491
Vinci Compass Investments Ltd
VINP
$627M
| $160K | ﹤0.01% |
17,732
+900
| +5% | +$8.97K |
|
3492
Fortress Biotech
FBIO
$99M
| $159K | ﹤0.01% |
16,220
-13,153
| -45% | -$146K |
|
|
PATI
3493
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
| $159K | ﹤0.01% |
22,609
-1,100
| -5% | -$8.88K |
|
|
VIVS
3494
VivoSim Labs
VIVS
$1.15M
| $158K | ﹤0.01% |
9,338
-653
| -7% | -$13.1K |
|
3495
Daxor
DXR
$59.5M
| $157K | ﹤0.01% |
17,121
+200
| +1% | +$2.2K |
|
3496
Axogen
AXGN
$2.58B
| $156K | ﹤0.01% |
15,600
+5,600
| +56% | +$62.2K |
|
|
BLPH
3497
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $155K | ﹤0.01% |
171,799
-24,392
| -12% | -$25K |
|
3498
Birks Group
BGI
$6.5M
| $154K | ﹤0.01% |
19,400
-10,200
| -34% | -$54.3K |
|
|
WKME
3499
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $154K | ﹤0.01% |
13,800
+1,700
| +14% | +$14.9K |
|
3500
Amneal Pharmaceuticals
AMRX
$6.15B
| $152K | ﹤0.01% |
76,400
-65,500
| -46% | -$147K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.